Earnings call transcript: Biogen Q2 2025 earnings beat forecasts, stock rises. Biogen Inc. (BIIB) reported strong financial results for the second quarter of 2025, significantly surpassing earnings expectations. The company achieved an earnings per share (EPS) of $5.47, beating the forecasted $3.99 by 37.09%. Revenue also exceeded expectations, reaching $2.6 billion against a projected $2.32 billion, marking a 12.07% surprise. Following these results, Biogen’s stock rose by 5.02% in pre-market trading. According to InvestingPro data, the company maintains a healthy gross profit margin of 75.65% and trades at an attractive P/E ratio of 12.87, suggesting potential value for investors.

Earnings call transcript: Biogen Q2 2025 earnings beat forecasts, stock rises

Biogen Inc. reported strong Q2 2025 financial results, surpassing earnings and revenue forecasts. The company's EPS of $5.47 exceeded expectations by 37.09%, with revenue reaching $2.6 billion versus a projected $2.32 billion. The stock rose 5.02% in pre-market trading, supported by a 75.65% gross profit margin and a 12.87 P/E ratio.